Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.


We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.

DOI: 10.1128/AAC.01609-15

6 Figures and Tables

Cite this paper

@article{Albayati2015NovelBA, title={Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.}, author={Zaineb A Fadhel Albayati and Manjula Sunkara and Suzannah M. Schmidt-Malan and Melissa Karau and Andrew J. Morris and James M. Steckelberg and Robin Patel and Philip J. Breen and Mark S . Smeltzer and Karen G Taylor and Kevyn E Merten and William M. Pierce and Peter A. Crooks}, journal={Antimicrobial agents and chemotherapy}, year={2015}, volume={60 3}, pages={1865-8} }